Characteristics, immunological response & treatment outcomes of HIV-2 compared with HIV-1 & dual infections (HIV 1/2) in Mumbai

Indian Journal of Medical Research

Volumn 132, Issue 12, 2010, Pages 683-689

  Chiara, Montaldo ^a   Rony, Zachariah ^a   Homa, Mansoor ^a   Bhanumati, Varghese ^a   Ladomirska, Joanna ^a   Manzi, M ^a   Wilson, N ^c   Alaka, Deshpande ^b   Harries, A D ^c,d  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b JJ Hospital Mumbai   (India)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

ART; HIV 1; HIV 2; Mumbai; Treatment outcomes

Indexed keywords

ABACAVIR; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; COMPARATIVE STUDY; CONVALESCENCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IMMUNE RESPONSE; INDIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; PATIENT TRANSPORT; PRESCHOOL CHILD; SCHOOL CHILD; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CD4 LYMPHOCYTE COUNT; CITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; PREVALENCE; RETROSPECTIVE STUDY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CITIES; FEMALE; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; IMMUNOASSAY; INDIA; MALE; PREVALENCE; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 78751487654     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kanki PJ, Travers KU, Mboup S, Hsieh CC, Marlink RG, Guèye-Ndiaye A, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343: 943-6.
2. Horsburg CR, Holmbreg SD. The global distribution of human immunodeficiency virus type 2 (HIV-2) infection. Transfusion 1988; 343: 943-6.
3. Rübsamen-Waigmann H, Maniar J, Gerte S, Brede HD, Dietrich U, Mahambre G, et al. High proportion of HIV-2 and HIV-1/2 double-reactive sera in two Indian states, Maharashtra and Goa: first appearance of an HIV-2 epidemic along with an HIV-1 epidemic outside of Africa. Zentralbl Bakteriol 1994; 280: 398-402.
4. Kulkarni S, Thakar M, Rodrigues J, Banerjee K. HIV-2 antibodies in serum samples from Maharashtra state. Indian J Med Res 1992; 95: 213-5.
5. Babu PG, Saraswathi NK, Devapriya F, John TJ. The detection of HIV-2 infection in southern India. Indian J Med Res 1993; 97: 49-52.
6. Marlink R, Lessons from the second virus, HIV-2. AIDS 1996; 10: 689-99.
7. Whittle H, Morris J, Todd J, Corrah T, Sabally S, Bangali J, et al. HIV-2-infected patients survive longer than HIV-1 infected patients. AIDS 1994; 8: 1617-20.
8. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265: 1587-90.
9. Jaffar S, Wilkins A, Ngom PT, Sabally S, Corrah T, Bangali JE, et al. Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 327-2.
10. Schim van der Loeff M, Jaffar S, Aveika A, Sabally S, Corrah T, Harding E, et al. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in the Gambia. AIDS 2002; 16: 1775-83
11. Matheron S, Courpotin C, Simon F, Di Maria H, Balloul H, Bartzack S, et al. Vertical transmission of HIV-2. Lancet 1990; 335: 1103-4.
12. Andreasson PA, Dias F, Naucler A, Andersson S, Biberfeld G. A prospective study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau. AIDS 1993; 7: 989-3.
13. Adjorlolo-Johnson G, Decock KM, Ekpini E, Vetter KM, Sibailly T, Brattegaard K, et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994; 272: 462-6.
14. De Cock K, Zadi F, Adjorolo G, Diallo M, Sassan-Morokro M, Ekpini E, et al. Retrospective study of maternal HIV-1 and HIV-2 infections and child survival in Abidjan, Cote d'Ivoire. BMJ 1994; 308: 441-3.
15. Rodés B, Sheldon J, Toro C, Jiménez V, Álvarez MA, Soriano V. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother 2006; 57: 709-13.
16. Matheron S, Damond F, Benard A, Taieb A, Campa P. CD4 recovery in treated HIV-2 infected adults is lower than expected: results from the France ANRS CO5 HIV-2 cohort. AIDS 2006; 20: 459-62.
17. Rouet F, Ekouevi DK, Inwoley A, Chaix M-L, Burgard M, Bequet L, et al. Field evaluations of a rapid human immunodeficiency virus serial serological testing algorithm for diagnosis and differentiation of HIV type 1 (HIV-1), HIV-2 and dual HIV-1-HIV-2 infections in West African pregnant women. J Clin Microbiol 2004; 42: 4147-53.
18. Ampofo WK, Koyanagi Y, Brandful J, Ishikawa K, Yamamoto N. Seroreactivity clarification and viral load quantification in HIV-1 and HIV-2 infections in Ghana. J Med Dent Sci 1999; 46: 53-62.
19. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundu G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival and drug resistance. Lancet 2002; 360: 34-40.
20. Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, Peter TF, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005; 40: 336-43.
21. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18: 887-95.
22. Stringer JSA, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia - feasibility and early outcomes. JAMA 2006; 296: 782-93.
23. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants. AIDS 2008; 22: 873-82.
24. NACO. National AIDS HIV Sentinel Surveillance and HIV Estimation in India 2007. A Technical Brief' and 'Note on HIV sentinel surveillance and HIV estimation. Available from: http://www.nacoonline.org/Quick_Links/HIV_Data/, accessed on August 1, 2009.
25. World Health Organisation. Scaling up antiretroviral therapy in resource-limited settings. Treatment guidelines for a public health approach. Geneva, Switzerland: WHO; 2006.
26. Witvrouw M. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. Antivir Chem Chemother 1999; 10: 211-7.
27. Parkin NT, Schapiro JM. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther 2004; 9: 3-12.
28. Smith NA, Shaw T, Berry N, Vella C, Okorafor L, Taylor D, et al. Antiretroviral therapy for HIV-2 infected patients. J Infect 2001; 42: 126-33.
29. Adje-Toure C, Cheingsong R, Garcia-Lerma G, Eholie S, Borget MY, Bouchez JM, et al. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 2003; 17 (Suppl 3): S49-S54.
30. Sagoe K, Mingle J, Affram R, Britton S, Dzokoto D, Sonnerborg A. Virological characterization of dual HIV-1/HIV-2 seropositivity and infections in Southern Ghana. Ghana Med J 2008; 42: 16-21.
31. Peeters M, Gershy-Damet G-M, Fransen K, Koffi K, Coulibaly M, Delaporte E, et al. Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in Cote d'Ivoire. Lancet 1992; 340: 339-40.